<DOC>
	<DOCNO>NCT02047708</DOCNO>
	<brief_summary>Many patient scleroderma damage kidney cause disease . There limited evidence treatment prevent damage stop progressing . Blocking substance blood call endothelin help treat aspect scleroderma . The purpose study see effective new endothelin blocker call Zibotentan treat patient scleroderma go develop reduce kidney function complication . It give addition accept treatment use scleroderma . There three part study different group patient : - ZEBRA 1 patient mild moderate kidney disease cause scleroderma - ZEBRA 2A patient severe , acute form kidney disease cause scleroderma ( scleroderma renal crisis ) require dialysis - ZEBRA 2B patient scleroderma renal crisis dialysis</brief_summary>
	<brief_title>Zibotentan Better Renal Scleroderma Outcome Study</brief_title>
	<detailed_description>This 3-part study ( Zebra 1 , 2A 2B ) explore safety therapeutic potential Zibotentan acute chronic renal complication Scleroderma . Trial duration 52 week Zebra 1 2A ( 1 2 week ZEBRA 2B 1 year follow data ) . Scleroderma ( Systemic sclerosis ) multisystem rheumatic disease result vascular damage fibrosis target organs.This project focus specifically evaluation treatment renal disease scleroderma . Renal involvement Scleroderma occur variety different pathologiesÍ¾ hypertensive scleroderma renal crisis ( SRC ) dramatic manifestation milder form chronic renal disease frequent represent important clinical feature .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Scleroderma , Localized</mesh_term>
	<criteria>1 . Adults scleroderma : 2 . CKD 2/3 ( ZEBRA 1 ) 3 . Renal crisis dialysis ( ZEBRA 2A ) 4 . Renal crisis dialysis ( ZEBRA 2B ) 1 . Previous use endothelin receptor antagonist within 3 month study start 2 . Significant abnormality liver function testing ( ALT , ALP , Bilirubin ) three time upper limit normal ) 3 . Patients body weight &lt; 40kg . 4 . Patients condition prevent compliance protocol failure adhere therapy . 5 . Patients life threaten condition . 6 . Patients know hypersensitivity Zibotentan excipients 7 . Previous history epilepsy CNS AEs , neurologic symptoms sign consistent acute evolve spinal cord compression , CNS metastases 8 . Patients baseline leave ventricular ejection fraction &lt; 40 % ( prior scleroderma renal crisis ) , patient acute myocardial infarction within six month patient judge trial clinician unacceptable risk cardiac complication . 9 . History chronic alcohol drug abuse condition associate poor compliance judge investigator 10 . Patients receive cyclosporin A within 1 week screen expect receive agent study . 11 . Patients receive investigational agent month prior screen . These patient may eligible month washout period , still within 112 month onset Scleroderma renal crisis . 12 . Active malignancy neoplastic disease previous 12 month 13 . Women rely oestrogencontaining contraceptive ( due potential drug interaction Zibotentan ) . 14 . Females pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>